Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Lockdown

Sector expert Michael Ballanger interprets year-end investment tactics by looking back at a childhood encounter. "Gold is money; everything else is credit." —J.P. Morgan My first faithful dog Fido (circa 1963) and I used to play a game years ago before his eyes and ...
Streetwise Reports | November 27, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...
Streetwise Reports | November 5, 2019 |

Operational Improvements Boost Yamana

Yamana Gold Inc. (YRI:TSX; AUY:NYSE; YAU:LSE) (3.65) has seen another quarter of improving operations, with earnings above expectations, mostly because of strength at El Penon. In the next quarter, expected improvement at Cerro Moro and Jacobina, should continue this t...
Streetwise Reports | October 31, 2019 |

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...
Streetwise Reports | September 25, 2019 |

Buzz on the Bullboards: Pulling gains out of volatile territory

As the global economy navigates uncertainties, investors have been watching the performance of key stock markets for insights into prevailing sentiment and economic health. Over the past week, the TSX and the trio of indices on Wall Street – the Dow Jones Industrial A...
Jonathon Brown | March 28, 2024 |

Cheap for a Reason: Osisko Gold Royalties and Fortuna

Osisko Gold Royalties Ltd. (OR:TSX; OR:NYSE, US$9.69) has moved further away from the pure royalty model with the acquisition of Bakerville Gold Mines for equity valued (at the time of the bid) at CA$338 million. Based on the August PEA (preliminary economic assessment...
Streetwise Reports | October 1, 2019 |

Is ValOre Primed for PGM’s Perfect Storm?

It has all the makings of a perfect storm of opportunity, in spite of the recent onset of a long-awaited cyclical bear market for North America’s capital markets. A surging market for platinum prices and other platinum group metals (PGMs) over the past sev...
Marc Davis | March 31, 2020 |

Aphria, Canopy Growth, EXMceuticals - Europe becomes the largest cannabis market

The consulting firm Prohibition Partners expects Europe to grow into the world's largest market for legal cannabis products in the next five years. Germany will become by far the largest market for medical cannabis products. According to the experts, Europe will thus overtake ...
Mario Hose | February 11, 2020 |
1 2 3 4 5 6